Ethics Committees in India: Past, present and future.

Area of Science:

• Clinical research ethics
• Regulatory affairs in India
• Participant protection in clinical trials

Background:

• The evolution of Ethics Committees (ECs) in India is traced, highlighting their central role in protecting clinical trial participants.
• Key regulatory milestones include the ICMR Policy Statement (1980), Schedule Y (1988), Amended Schedule Y (2005), and ICMR Guidelines (2006).
• Identified challenges include inadequate training, administrative support, lack of SOPs, and heavy workloads, alongside the impact of the Clinical Trial Registry - India (CTRI) and voluntary accreditation.

Purpose of the Study:

• To examine the historical evolution and current status of Ethics Committees in India.
• To analyze the impact of regulatory amendments on EC functioning and participant safety.
• To propose future strategies for improving EC oversight and effectiveness.

Main Methods:

• Historical review of regulatory documents and guidelines pertaining to ECs in India.
• Analysis of the current landscape of ECs, including registration with CDSCO.
• Exploration of proposed future methods for EC oversight and performance assessment.

Main Results:

• India experienced rapid growth in clinical research following Schedule Y amendments, followed by a decline, with ECs at the core.
• Over 1000 ECs are registered with CDSCO due to regulatory reforms, but their impact on participant safety is yet to be fully assessed.
• ECs have transitioned from simple protocol approvers to accredited bodies, though further development is necessary.

Conclusions:

• Ethics Committees in India have evolved significantly, moving towards more efficient and accredited functioning.
• Despite progress, substantial work remains to be done by and for Ethics Committees to ensure optimal participant protection.
• Future directions include enhanced oversight, on-site monitoring, central ECs for multicentric studies, and metrics for evaluating EC performance.